TY - JOUR
T1 - Patient-reported outcomes during and after hepatitis C virus direct-acting antiviral treatment among people who inject drugs
AU - Cheng, Qinglu
AU - Cunningham, Evan B.
AU - Shih, Sophy
AU - Amin, Janaki
AU - Bruneau, Julie
AU - Artenie, Adelina A.
AU - Powis, Jeff
AU - Litwin, Alain
AU - Cooper, Curtis
AU - Dalgard, Olav
AU - Hellard, Margaret
AU - Bruggmann, Philip
AU - Marks, Philippa
AU - Lacombe, Karine
AU - Stedman, Catherine
AU - Read, Phillip
AU - Hajarizadeh, Behzad
AU - Dunlop, Adrian J.
AU - Conway, Brian
AU - Feld, Jordan
AU - Dore, Gregory J.
AU - Grebely, Jason
AU - SIMPLIFY and D3FEAT study groups
AU - Crawford, Sione
AU - Swan, Tracy
AU - Byrne, Jude
AU - Lacalamita, Melanie
AU - Erratt, Amanda
AU - Shaw, Ineke
AU - Siriragavan, Sharmila
AU - Quiene, Sophie
AU - Petoumenos, Kathy
AU - Schmid, Patrick
AU - Castro, Erika
AU - Moriggia, Alberto
AU - Daulouede, Jean Pierre
AU - Fraser, Christopher
AU - Gane, Ed
AU - Matthews, Gail
AU - Kronborg, Ian
AU - Shaw, David
AU - Norton, Brianna
AU - Thurnheer, Maria Christine
AU - Weltman, Martin
AU - Dillon, John
AU - Kessler, Simone
AU - Knapp, Cornelia
AU - Oprandi, Lorenza
AU - Messina, Paola
AU - Pantic, Marzia
AU - Le Cam, Manuela
AU - Maitre, Cecilia
AU - Andreassen, Jessica
AU - Melkeraaen, Ingunn
AU - Tollefsen, Merete Moen
AU - Pagarigan, Hannah
AU - Milne, Rozalyn
AU - Mason, Kate
AU - Kaznowski, Diana
AU - Zou, Lily
AU - Bouchard, Rachel
AU - Kotsoros, Barbara
AU - Muir, Miriam
AU - Milloy, Jessica
AU - Oliver, Victoria
AU - Noonan, Tracy
AU - Sevehon, Alison
AU - Hazelwood, Susan
AU - Hall, Michelle
AU - Hagenauer, Michelle
AU - Liddle, Rachel
AU - Ferguson, Catherine
AU - Agyemang, Linda
AU - Patel, Hiral
AU - Soloway, Irene
AU - Cerocchi, Orlando
AU - Lacalamita, Melanie
AU - Fragomeli, Vincenzo
AU - Gilliver, Rosie
AU - Lothian, Rebecca
AU - Cleary, Shirley
AU - Johnston, Linda
AU - Middleton, Sarah
AU - D'Amico, Ronald
AU - McGovern, Barbara
AU - Anderson, Jonathan
AU - Zhong, Ze
AU - Keane, Fiona
AU - Tatsch, Fernando
AU - Brainard, Diana
AU - McHutchison, John
PY - 2023/6
Y1 - 2023/6
N2 - Objectives: People who inject drugs (PWID) are at a high risk of hepatitis C virus (HCV) infection. HCV cure is associated with improved patient-reported outcomes (PROs), but there are little data among PWID. This study aimed to assess the change in PROs during and after HCV direct-acting antiviral (DAA) treatment. Methods: This analysis used data from 2 clinical trials of DAA treatment in PWID. PROs assessed included health-related quality of life, social functioning, psychological distress, housing, and employment. Generalized estimating equations and group-based trajectory modeling were used to assess changes in PROs over time. Results: No significant changes in the 3-level version of EQ-5D scores, EQ visual analogue scale scores, social functioning, psychological distress, and housing were observed over the 108-week study period. There was a significant increase in the proportion of participants employed (18% [95% confidence interval (CI) 12%-23%] at baseline to 28% [95% CI 19%-36%] at the end of the study). Participants were more likely to be employed at 24 weeks and 108 weeks after commencing treatment. Having stable housing increased the odds of being employed (odds ratio 1.70; 95% CI 1.00-2.90). The group-based trajectory modeling demonstrated that most outcomes remained stable during and after DAA treatment. Conclusions: Although no significant improvement was identified in health-related quality of life after HCV DAA treatment, there was a modest but significant increase in employment during study follow-up. The study findings support the need for multifaceted models of HCV care for PWID addressing a range of issues beyond HCV treatment to improve quality of life.
AB - Objectives: People who inject drugs (PWID) are at a high risk of hepatitis C virus (HCV) infection. HCV cure is associated with improved patient-reported outcomes (PROs), but there are little data among PWID. This study aimed to assess the change in PROs during and after HCV direct-acting antiviral (DAA) treatment. Methods: This analysis used data from 2 clinical trials of DAA treatment in PWID. PROs assessed included health-related quality of life, social functioning, psychological distress, housing, and employment. Generalized estimating equations and group-based trajectory modeling were used to assess changes in PROs over time. Results: No significant changes in the 3-level version of EQ-5D scores, EQ visual analogue scale scores, social functioning, psychological distress, and housing were observed over the 108-week study period. There was a significant increase in the proportion of participants employed (18% [95% confidence interval (CI) 12%-23%] at baseline to 28% [95% CI 19%-36%] at the end of the study). Participants were more likely to be employed at 24 weeks and 108 weeks after commencing treatment. Having stable housing increased the odds of being employed (odds ratio 1.70; 95% CI 1.00-2.90). The group-based trajectory modeling demonstrated that most outcomes remained stable during and after DAA treatment. Conclusions: Although no significant improvement was identified in health-related quality of life after HCV DAA treatment, there was a modest but significant increase in employment during study follow-up. The study findings support the need for multifaceted models of HCV care for PWID addressing a range of issues beyond HCV treatment to improve quality of life.
KW - direct-acting antiviral
KW - health-related quality of life
KW - hepatitis C
KW - patient-reported outcomes
UR - https://www.scopus.com/pages/publications/85148666853
U2 - 10.1016/j.jval.2022.12.016
DO - 10.1016/j.jval.2022.12.016
M3 - Article
C2 - 36646278
AN - SCOPUS:85148666853
SN - 1098-3015
VL - 26
SP - 883
EP - 892
JO - Value in Health
JF - Value in Health
IS - 6
ER -